Investor Relations

Corporate Profile

3DBio, headquartered in New York City (Long Island City, Queens), is a clinical-stage biotechnology company and leader in regenerative medicine using novel 3D-bioprinting and materials technologies to deliver safe, functional and personalized living tissues and organs, engineered on-demand for patients. 3DBio’s pioneering approach develops living tissue implants with structural and functional integrity with a four-part technology platform, including: novel and proprietary 3D-bioprinter (GMPrint™), bio-ink (ColVivo™), specialized cell culture system, and implantable protective shell (Overshell Technology). Today, 3DBio is breaking new ground with a clinical trial underway to treat Microtia, three additional programs nearing the clinic, and multiple life-changing treatment approaches in development. 3DBio is committed to providing healthcare professionals with safe and functional implant solutions delivering optimal patient outcomes.

Latest Updates

Pod cast IconNews
October 23, 2021

3DBio on Finding Genius Podcast

Finding Genius Podcast (Oct. 23, 2021 Episode) 3DBio: Printing Living Human Tissues for Therapeutic Applications   Press play to learn: The most common problems with synthetic implants How 3D bioprinting…
Living ear tissue bioprinted by 3DBio Therapeutics.News
November 5, 2020

Axios: Bioprinted Living Tissue Aims for Clinical Trial

Bryan Walsh, author of Future Axios Living ear tissue bioprinted by 3DBio Therapeutics. Photo: 3DBio Therapeutics A startup is applying for clinical trials of its method of 3D bioprinting living ear…
Human Model Background ImagePress Releases
December 6, 2019

3DBio Therapeutics Receives FDA Rare Pediatric Disease Designation for AuriNovo™ for Ear Reconstruction in Microtia Patients

NEW YORK, December 6, 2019 /PRNewswire/ — 3DBio Therapeutics, an emerging leader in the field of 3D-bioprinting for human therapeutic use, today announced that the U.S. Food and Drug Administration (FDA) has granted…